Videos / Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Description

In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Additional resources

NCIRS FAQ: Respiratory syncytial virus (RSV) FAQs | NCIRS.
NCIRS Fact Sheet – state funding of Nirsevimab, eligibility criteria by state: State and territory nirsevimab program summary 2025.pdf

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Dr Andrew Leech

Managing Paediatric Anxiety in General Practice

Prof Brendon Yee

OSA – Which Test for Which Patient

Dr Sonia Davison

Musculoskeletal Health in Menopause

Mr David Gardner

AHPRA-Proof Your Practice – Social Media Risks for GPs

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

08 July 2025

expert

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine